Galmed Pharmaceuticals
GLMD
24 hedge funds and large institutions have $23.4M invested in Galmed Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0.02% less ownership
Funds ownership: 0.19% → 0.17% (-0.02%)
4% less funds holding
Funds holding: 25 → 24 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
34% less capital invested
Capital invested by funds: $35.4M → $23.4M (-$12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
+$2.4M |
| 2 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$453K |
| 3 |
Squarepoint
New York
|
+$109K |
| 4 |
Morgan Stanley
New York
|
+$88.2K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$58.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.11M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$1.39M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$1.11M |
| 4 |
Renaissance Technologies
New York
|
-$198K |
| 5 |
VF
Virtu Financial
New York
|
-$71K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
26
Virtu Financial
New York
| – | -$71K | -83 | Closed |
|
|
LNWWM
27
Laird Norton Wetherby Wealth Management
San Francisco,
California
| – | -$48K | -56 | Closed |
|
28
UBS Group
Zurich,
Switzerland
| – | -$3K | -4 | Closed |
|
|
CG
29
Cutler Group
San Francisco,
California
| – | +$817 | +1 | New |
|
GLMD Hedge Fund Activity: Q3 2020 in Review
24 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2020, worth a combined $23.4M — down 34% from $35.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of GLMD and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.
The largest buyer was Ibex Investors, adding an estimated $2.4M. The largest seller was Vivo Capital, exiting entirely with an estimated $4.11M sold.
- 24 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2020, down from 25 in Q2 2020.
- Funds reported $23.4M of Galmed Pharmaceuticals stock for Q3 2020, down 34% quarter-over-quarter.
- 4 funds opened new Galmed Pharmaceuticals positions in Q3 2020 and 5 closed out, a net change of -1 holder.
- The largest Galmed Pharmaceuticals buyer in Q3 2020 was Ibex Investors, an estimated $2.4M added.
- The largest Galmed Pharmaceuticals seller in Q3 2020 was Vivo Capital, an estimated $4.11M sold.
Based on aggregated 13F filings for Q3 2020.